Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
- PMID: 11571571
- DOI: 10.1038/sj.gt.3301541
Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
Abstract
Gene therapy using recombinant adeno-associated virus vectors (rAAV) is generally considered safe. During the course of a study designed to determine the long-term efficacy of rAAV-mediated gene therapy initiated in newborn mice with the lysosomal storage disease, mucopolysaccharidosis type VII (MPSVII), a significant incidence of hepatocellular carcinomas and angiosarcomas was discovered. A hepatocellular carcinoma was first detected in a 35-week-old mouse and by 72 weeks of age, three out of five rAAV-treated MPSVII mice had similar lesions. These types of tumors had not been seen previously in long-term studies of MPSVII mice using recombinant enzyme or bone marrow transplantation. In an attempt to ascertain whether mouse strain or GUSB expression confers susceptibility to tumor formation, we histopathologically examined untreated normal mice of the same strain, untreated MPSVII mice, and normal mice overexpressing human GUSB for the presence of tumors and increased hepatocyte replication. The results of these studies do not indicate that MPSVII mice or mice overexpressing human GUSB are susceptible to tumor formation; however, the number of animals examined is too small to draw definitive conclusions. Results from quantitative PCR performed on the tumor samples suggest that the tumors are probably not caused by an insertional mutagenesis event followed by the clonal expansion of a transformed cell. In a separate study, a relatively large group of mice injected with varying doses and types of rAAV vectors had no evidence of hepatic or vascular tumors. Although the mechanism of tumor formation is currently unknown, the tumorigenic potential of rAAV vectors must be rigorously determined in long-term in vivo studies.
Comment on
-
Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer.Gene Ther. 2001 Sep;8(17):1291-8. doi: 10.1038/sj.gt.3301420. Gene Ther. 2001. PMID: 11571565
Similar articles
-
Recombinant adeno-associated virus derived vectors (rAAV2) efficiently transduce ovarian and hepatocellular carcinoma cells--implications for cancer gene therapy.Acta Pol Pharm. 2009 Jan-Feb;66(1):93-9. Acta Pol Pharm. 2009. PMID: 19226976
-
Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.Clin Cancer Res. 2005 Feb 1;11(3):1342-7. Clin Cancer Res. 2005. PMID: 15709207
-
NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies).Natl Toxicol Program Tech Rep Ser. 1993 Aug;443:1-321. Natl Toxicol Program Tech Rep Ser. 1993. PMID: 12595920
-
Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives.Gene Ther. 2004 Oct;11 Suppl 1:S26-32. doi: 10.1038/sj.gt.3302366. Gene Ther. 2004. PMID: 15454954 Review.
-
Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.Trans Am Clin Climatol Assoc. 2003;114:337-51; discussion 351-2. Trans Am Clin Climatol Assoc. 2003. PMID: 12813929 Free PMC article. Review.
Cited by
-
Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.Hepatology. 2021 Jun;73(6):2223-2237. doi: 10.1002/hep.31570. Epub 2021 May 21. Hepatology. 2021. PMID: 32976669 Free PMC article.
-
A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning.J Vis Exp. 2015 Jun 22;(100):e52859. doi: 10.3791/52859. J Vis Exp. 2015. PMID: 26131591 Free PMC article.
-
Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog.Mol Ther Methods Clin Dev. 2023 Nov 14;31:101159. doi: 10.1016/j.omtm.2023.101159. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 38094200 Free PMC article.
-
Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities.Int J Mol Sci. 2021 May 23;22(11):5490. doi: 10.3390/ijms22115490. Int J Mol Sci. 2021. PMID: 34070997 Free PMC article. Review.
-
Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome).Ther Clin Risk Manag. 2022 Dec 22;18:1143-1155. doi: 10.2147/TCRM.S351300. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 36578769 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases